Chitosan modifies glycemic levels in people with metabolic syndrome and related disorders: meta-analysis with trial sequential analysis.

ABSTRACT: Background: Chitosan supplementation has been shown to modulate glycemic levels; however, studies have reported conflicting results. The present meta-analysis with trial sequential analysis was conducted to verify the overall influence of chitosan on glycemic levels in patients with metabolic syndrome.

Methods: The PubMed, Cochrane library, and EMBASE databases were systematically searched for randomized controlled studies of chitosan intake and glycemic levels.

Results: A total of ten clinical trials including 1473 subjects were included in this meta-analysis. Pooled effect sizes were determined by random-effects meta-analysis. Subgroup analysis was performed to analyze the sources of heterogeneity and their influence on the overall results. The results revealed a significant reduction in fasting glucose levels (SMD: -?0.39?mmol/L, 95% CI: -?0.62 to -?0.16) and hemoglobin A1c (HbA1c) levels (SMD: -1.10; 95% CI: -?2.15 to -?0.06) following chitosan supplementation but no effect on insulin levels (SMD: - 0.20 pmol/L, 95% CI: - 0.64 to 0.24). Subgroup analyses further demonstrated significant reductions in fasting glucose levels in subjects administered 1.6-3?g of chitosan per day and in studies longer than 13?weeks. Trial sequential analysis of the pooled results of the hypoglycemic effect demonstrated that the cumulative Z-curve crossed both the conventional boundary and trial sequential monitoring boundary for glucose and HbA1c.

Conclusions: The glucose level of patients who are diabetic and obese/overweight can be improved by supplementation with chitosan for at least 13?weeks at 1.6-3?g per day. Additional clinical research data are needed to confirm the role of chitosan, particularly in regulating glycosylated hemoglobin and insulin.

SUBMITTER: Guo W 

PROVIDER: S-EPMC7709411 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature